ERG and prostate cancer: A recurrent gene fusion TMPRSS2-ERG was observed in more than fifty percent of prostate cancer cases with the deletion of del(q22) and t(7;21)(1,26–28), resulting in translocation of the ERG gene (21q22.3) or the ETV1 gene (7p21.2) to the TMPRSS2 gene (21q22.2) promoter region [44,45].